시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 폰빌레브란트병 시장 보고서(2025년)
Von Willebrand Disease Global Market Report 2025
상품코드 : 1731060
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,546,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,462,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,378,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

폰빌레브란트병 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 툴의 사용 증가, 희귀질환에 대한 원격 의료 서비스의 확대 등의 요인에 의한 것으로 예측됩니다. 이 기간의 주요 동향으로는 유전자 치료 접근의 발전, 진단에 있어서의 인공지능의 통합, 비침습적 진단 툴의 혁신, 신규 약물전달 시스템의 도입, 환자 교육을 위한 디지털 헬스 플랫폼의 개발 등을 들 수 있습니다.

출혈성 질환의 유병률 증가는 폰빌레브란트병 시장의 성장을 가속할 것으로 예측됩니다. 출혈성 질환으로 진단되는 사례 증가는 의료 지식과 진단 도구의 진보로 헬스케어 전문가가 이전에 알지 못했던 병태를 발견할 수 있게 된 것에 기인하고 있습니다. 폰 빌레브란트병 치료는 혈액 응고를 개선하고 과도한 출혈을 최소화하며 전반적인 삶의 질을 향상시켜 환자에게 도움이 됩니다. 영국 혈우병 센터 의사 조직의 보고서에 따르면 영국에서 혈우병 A의 신규 등록 건수는 2021년 16건에서 2022년 19건으로 증가했습니다.

폰빌레브란트병 시장의 주요 기업은 치료 효과 향상, 출혈 에피소드 감소, 환자 결과 개선을 목적으로 폰빌레브란트병 인자(VWF) 농축 제제 등의 혁신적인 치료법 개발에 주력하고 있습니다. VWF 농축액은 폰 빌레브란트병 환자의 출혈을 치료하고 예방하는 데 사용되는 약물입니다. 폰 빌레브란트병은 폰 빌레브란트 인자(VWF)의 결핍이나 기능 이상으로 인해 발생하는 유전성 혈액 응고 질환입니다. Octapharma USA Inc.는 VWF 농축 제제인 Wilate가 미국 식품의약국(FDA)으로부터 승인되었다고 발표했습니다. 성인과 6세 이상 어린이의 출혈 빈도를 줄이기 위해 일상적인 예방 치료에 사용되는 정맥 주사용 동결 건조 분말 용액입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Von Willebrand disease (VWD) is a genetic bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein that plays a crucial role in blood clotting. The severity of the disorder depends on the amount and functionality of von Willebrand factor in the blood.

The main types of von Willebrand disease include type 1, type 2, and type 3. Type 1 is a mild form of the disorder, where individuals have lower-than-normal levels of von Willebrand factor, leading to difficulties in proper blood clotting. The drugs used to manage VWD include antihemophilic factor, coagulation factor VIII complex, von Willebrand factor, desmopressin acetate, and others, with severity levels ranging from mild to severe. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used by a variety of end-users, such as hospitals, specialty clinics, homecare providers, and others.

The von willebrand disease market research report is one of a series of new reports from The Business Research Company that provides von willebrand disease market statistics, including von willebrand disease industry global market size, regional shares, competitors with a von willebrand disease market share, detailed von willebrand disease market segments, market trends and opportunities, and any further data you may need to thrive in the von willebrand disease industry. This von willebrand disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The von willebrand disease market size has grown strongly in recent years. It will grow from $1.74 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to several factors, including increased awareness of rare bleeding disorders, higher diagnosis rates of von Willebrand disease, growth in research funding for blood disorders, improved access to healthcare, and a rising use of prophylactic treatments in hemophilia care.

The von willebrand disease market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The projected growth during the forecast period can be attributed to factors such as the increasing development of gene therapies for bleeding disorders, rising investment in biotechnology research, a growing demand for non-invasive diagnostic techniques, the increasing use of digital health tools for disease monitoring, and the expansion of telemedicine services for rare diseases. Key trends for this period include advancements in gene therapy approaches, the integration of artificial intelligence in diagnostics, innovations in non-invasive diagnostic tools, the introduction of novel drug delivery systems, and the development of digital health platforms for patient education.

The increasing prevalence of bleeding disorders is expected to drive the growth of the von Willebrand disease market. Bleeding disorders refer to medical conditions that impair the body's ability to form blood clots, resulting in prolonged or excessive bleeding. The rise in diagnosed cases of bleeding disorders can be attributed to advancements in medical knowledge and diagnostic tools, which have enabled healthcare professionals to detect conditions that previously went unnoticed. Treatments for von Willebrand disease help patients by improving blood clotting, minimizing excessive bleeding, and enhancing their overall quality of life. For example, a report from the United Kingdom Haemophilia Centre Doctors' Organization revealed that new registrations of Hemophilia A in the UK increased from 16 in 2021 to 19 in 2022. This growing awareness and diagnosis of bleeding disorders are contributing to the expansion of the von Willebrand disease market.

Key players in the von Willebrand disease market are focusing on developing innovative treatments, such as von Willebrand factor (VWF) concentrate, to improve treatment effectiveness, reduce bleeding episodes, and enhance patient outcomes. VWF concentrate is a medication used to treat and prevent bleeding in patients with von Willebrand disease, which is caused by a deficiency or dysfunction of the von Willebrand factor. For instance, in April 2024, Octapharma USA Inc., a US-based pharmaceutical company, announced that Wilate, a VWF concentrate, had been approved by the U.S. Food and Drug Administration (FDA). Wilate is a lyophilized powder solution for intravenous injection used for routine prophylaxis to reduce the frequency of bleeding episodes in both adults and children aged six and older. The FDA granted Wilate orphan drug designation, providing it with up to seven years of market exclusivity to encourage the development of treatments for rare diseases.

In January 2024, Takeda Pharmaceutical Company, based in Japan, acquired Shire plc. for $62 billion. This acquisition aims to strengthen Takeda's position in rare diseases, plasma-derived therapies, and hematology, including treatments for von Willebrand disease and other bleeding disorders. Shire plc, a UK-based biotechnology company, focuses on developing therapies for rare diseases, including von Willebrand disease.

Major players in the von willebrand disease market are Pfizer Inc., Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Mayo Clinic, CSL Behring (a subsidiary of CSL Limited), Cleveland Clinic, Grifols S.A., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., Biotest AG, Versiti Inc., Fortis Healthcare Limited, LFB S.A., Hualan Biological Engineering Inc., Bio Products Laboratory Ltd. (BPL), Octapharma AG, Sino Biological Inc., Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the von willebrand disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in von willebrand disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the von willebrand disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The von willebrand disease market consists of sales of antifibrinolytic drugs, harmonal therapy, and clotting factor concentrates. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Von Willebrand Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on von willebrand disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for von willebrand disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The von willebrand disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Von Willebrand Disease Market Characteristics

3. Von Willebrand Disease Market Trends And Strategies

4. Von Willebrand Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Von Willebrand Disease Growth Analysis And Strategic Analysis Framework

6. Von Willebrand Disease Market Segmentation

7. Von Willebrand Disease Market Regional And Country Analysis

8. Asia-Pacific Von Willebrand Disease Market

9. China Von Willebrand Disease Market

10. India Von Willebrand Disease Market

11. Japan Von Willebrand Disease Market

12. Australia Von Willebrand Disease Market

13. Indonesia Von Willebrand Disease Market

14. South Korea Von Willebrand Disease Market

15. Western Europe Von Willebrand Disease Market

16. UK Von Willebrand Disease Market

17. Germany Von Willebrand Disease Market

18. France Von Willebrand Disease Market

19. Italy Von Willebrand Disease Market

20. Spain Von Willebrand Disease Market

21. Eastern Europe Von Willebrand Disease Market

22. Russia Von Willebrand Disease Market

23. North America Von Willebrand Disease Market

24. USA Von Willebrand Disease Market

25. Canada Von Willebrand Disease Market

26. South America Von Willebrand Disease Market

27. Brazil Von Willebrand Disease Market

28. Middle East Von Willebrand Disease Market

29. Africa Von Willebrand Disease Market

30. Von Willebrand Disease Market Competitive Landscape And Company Profiles

31. Von Willebrand Disease Market Other Major And Innovative Companies

32. Global Von Willebrand Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Von Willebrand Disease Market

34. Recent Developments In The Von Willebrand Disease Market

35. Von Willebrand Disease Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기